Rebecca Kraftick, PA
Medical · Lexington, KYNPI 1639112402
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,214 of the $6,212 with a category attached, or 83.9%. 31 manufacturers reported payments, led by Medtronic at 27.7% of the total. Reporting peaked in 2024 at $2,703 and has fallen 84.4% since, to $423 in 2025. Among medical clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 236 payments — averaging $26.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$1K
- Novartis$571
- E.r. Squibb & Sons, L.L.C.$409
- Amgen$383
- Pfizer$306
- plus $2K from 25 others
What the payments were for
- Travel & lodging$99916%
- Food & beverage$5,21484%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $1,723 |
| Abbott | 25 | $1,045 |
| Novartis | 36 | $571 |
| E.r. Squibb & Sons, L.L.C. | 11 | $409 |
| Amgen | 27 | $383 |
| Pfizer | 29 | $306 |
| AstraZeneca | 9 | $231 |
| Novo Nordisk | 13 | $215 |
| Johnson & Johnson | 12 | $190 |
| Merck | 9 | $143 |
| Boehringer Ingelheim | 3 | $129 |
| Bristol Myers Squibb | 1 | $116 |
| Boston Scientific | 4 | $93 |
| Scpharmaceuticals Inc. | 5 | $82 |
| Sanofi-aventis U.S. LLC | 5 | $80 |
| Atricure, Inc. | 4 | $75 |
| Alnylam Pharmaceuticals Inc. | 3 | $68 |
| Bayer | 4 | $57 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| Philips North America LLC | 2 | $32 |
| Chiesi USA, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Cvrx, Inc. | 2 | $25 |
| Avinger Inc. | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Abiomed | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Viz.ai, Inc. | 1 | $15 |
| Surmodics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$1,191
- CARDIOMEMS$409
- ZEPOSIA$339
How this compares
$6,212 in reported general payments places this provider in the 90th percentile of 222 medical providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 169 | $179,108 |
| JardianceEmpagliflozin | 128 | $105,712 |
| EntrestoSacubitril/Valsartan | 98 | $82,506 |
| XareltoRivaroxaban | 30 | $36,894 |
| Repatha SureclickEvolocumab | 28 | $24,215 |
| OzempicSemaglutide | 22 | $21,140 |
| FarxigaDapagliflozin Propanediol | 26 | $19,867 |
| Ranolazine ErRanolazine | 41 | $2,672 |
| Metoprolol Succinate | 184 | $1,734 |
| Valsartan | 72 | $1,646 |
| Atorvastatin Calcium | 157 | $1,594 |
| Amiodarone Hcl | 47 | $1,184 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 76 | $1,113 |
| Carvedilol | 204 | $1,028 |
| Rosuvastatin Calcium | 96 | $845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $306 | $179,108169 claims |
| Boehringer IngelheimJardiance | $129 | $105,712128 claims |
| NovartisEntresto | $571 | $82,50698 claims |
| Johnson & JohnsonXarelto | $190 | $36,89430 claims |
| Novo NordiskOzempic | $215 | $21,14022 claims |
| AstraZenecaFarxiga | $231 | $19,86726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 medical providers in Kentucky.
Other medical in Lexington
- Chasity HesterLexington$16K
- Allison ScottLexington$8K
- Micah BuckelLexington$7K
- Anna SchaeferLexington$6K
- Christen MontgomeryLexington$5K
- Tracy JohnsonLexington$5K
- Sarah GrimmLexington$5K
- Whitney WhitakerLexington$4K
- Hannah BurfordLexington$4K
- Kathryn AllenLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.